David D. Chang
President and CEO at Allogene Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Allogene Therapeutics Inc., 3 years.
Allogene Therapeutics Inc.
Director · President and CEO
Chief executive roles
Allogene Therapeutics Inc.
· President and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Allogene Therapeutics Inc. | Open-market sale | −47,763 | $2.47 | $117,975 |
| Feb 2, 2026 | Allogene Therapeutics Inc. | Open-market sale | −95,269 | $1.80 | $171,484 |
| Mar 14, 2025 | Allogene Therapeutics Inc. | Open-market sale | −46,668 | $1.96 | $91,469 |
| Feb 3, 2025 | Allogene Therapeutics Inc. | Open-market sale | −46,003 | $1.68 | $77,285 |
| Jan 24, 2025 | Allogene Therapeutics Inc. | Grant or award | +552,174 | — | — |
| May 16, 2024 | Allogene Therapeutics Inc. | Grant or award | +344,828 | $2.90 | $1,000,001 |
| Mar 14, 2024 | Allogene Therapeutics Inc. | Shares withheld for tax | −53,393 | $4.33 | $231,192 |
| Jan 25, 2024 | Allogene Therapeutics Inc. | Grant or award | +317,800 | — | — |
| Mar 22, 2023 | Allogene Therapeutics Inc. | Grant or award | +1,924,464 | — | — |
| Mar 14, 2023 | Allogene Therapeutics Inc. | Shares withheld for tax | −22,340 | $5.56 | $124,210 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.